Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

WideCells expands its reach to Spain

"The Spanish cord blood and stem cell storage market is one of the most established in Europe and accordingly is a highly prospective region for us,” said chief executive João Andrade
stem cell
The company is a specialist in the storage of stems cells from the umbilical cord, which could provide a potentially life-saving treatment for 82 blood-borne diseases

WideCells Group PLC announced it will launch its stem cell healthcare insurance plan in Spain following the product’s debut here in the UK and alongside its imminent roll-out in Brazil.

The local agent for the CellPlan, which costs £170 a year, will be a company called Stem Cell Banco Celulas Madre, a provider of stem cell storage services. Under the re-seller model, the tie-up should generate £50 per sale (after commissions and reinsurance costs).

READ: WideCells ready to ink deal that expands its reach to the Middle East, Africa and Asia-Pacific

In the same stock market announcement, WideCells confirmed its CellPlan e-commerce platform is now “fully live” in the UK. It is expected to be available in Spain by the end of the year.

Established market

"The Spanish cord blood and stem cell storage market is one of the most established in Europe and accordingly is a highly prospective region for us,” said chief executive João Andrade.

“Having successfully launched our CellPlan product in the UK, and with sales due to commence in Brazil in the near term, we now have an established framework and roll-out model which enables us to target new geographies quickly and with relatively low cost.”

On Wednesday, the company inked a deal that will take it and its stem cell services into the Middle East, Africa and Asia-Pacific regions.

Storage expert

The company is a specialist in the storage of stems cells from the umbilical cord, which could provide a potentially life-saving treatment for 82 blood-borne diseases, including leukaemia and lymphoma. The storage and research operation is the core WideCells business.

READ: WideCells Group ready for UK stem cell storage licence

It has also developed the aforementioned insurance plan that will allow people to pay for treatments using the umbilical material, which already now making money for the firm.

Alongside that it is creating a software platform that both educates and keeps medical professionals and parents up to date on new treatments and developments.

View full WDC profile View Profile

WideCells Group Timeline

Video
October 12 2017

Related Articles

1504120610_biotechLatest.jpg
October 23 2017
The company is poised for a milestone-rich period over the next year or so
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
Harley Street sign
December 07 2017
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use